What is the current Price Target for the Replimune Group, Inc. stock?

The average Replimune Group, Inc. target price is $21.63. This is 174.08% higher than the current stock price. The highest price target is 292.90%, the lowest is 115.46%. 8 Analysts have issued a price target Replimune Group, Inc. 2026 .

How high will the Replimune Group, Inc. stock rise?

No reliable answer can be given as to how high the Replimune Group, Inc. stock will rise. The performance of stocks, including the Replimune Group, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Replimune Group, Inc. stock today?

The performance of Replimune Group, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Replimune Group, Inc. stock fall?

The decline in Replimune Group, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Replimune Group, Inc. Forecast, price target & analysts

$7.37

6.59% today

Nasdaq, Apr 04, 09:18 pm CET

ISIN

US76029N1063

Symbol

REPL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Replimune Group, Inc. Target price 2025 - Analyst rating & recommendation

Replimune Group, Inc. Classifications & Recommendation:

Buy

100%

Replimune Group, Inc. Price Target

Target Price	$21.63
Price	$7.89
Potential	174.08% register free of charge
Number of Estimates	8

	8 Analysts have issued a price target Replimune Group, Inc. 2026 . The average Replimune Group, Inc. target price is $21.63. This is 174.08% register free of charge higher than the current stock price. The highest price target is $31.00 292.90% register free of charge , the lowest is $17.00 115.46% register free of charge .
	A rating was issued by 8 analysts: 8 Analysts recommend Replimune Group, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Replimune Group, Inc. stock has an average upside potential 2026 of 174.08% register free of charge . Most analysts recommend the Replimune Group, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Mar '24	2025 Estimates
Earnings Per Share $	-3.24	-3.00
	8.36%	7.41%
P/E		negative
EV/Sales		85.45

5 Analysts have issued a Replimune Group, Inc. forecast for earnings per share. The average Replimune Group, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.24	8.36%
2025	$-3.00 7.41% Unlock
2026	$-2.96 1.33% Unlock
2027	$-2.04 31.08% Unlock
2028	$-1.11 45.59% Unlock
2029	$-0.51 54.05% Unlock

Current	-2.51	0.80%
2025	-2.63 4.78% Unlock
2026	-2.67 1.52% Unlock
2027	-3.86 44.57% Unlock
2028	-7.11 84.20% Unlock
2029	-15.47 117.58% Unlock

Replimune Group, Inc....

Current Replimune Group, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
JP Morgan	Locked ➜ Locked	Locked	Feb 26 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 13 2025
BMO Capital	Locked ➜ Locked	Locked	Jan 22 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jan 22 2025
Jefferies	Locked ➜ Locked	Locked	Dec 04 2024
BMO Capital	Locked ➜ Locked	Locked	Nov 22 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 22 2024

Analyst Rating	Date
Locked JP Morgan: Locked ➜ Locked	Feb 26 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 13 2025
Locked BMO Capital: Locked ➜ Locked	Jan 22 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jan 22 2025
Locked Jefferies: Locked ➜ Locked	Dec 04 2024
Locked BMO Capital: Locked ➜ Locked	Nov 22 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 22 2024

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now